Sitafomin Tablets 50/850 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
MFDS item code 201505759 · Approved 2015.08.18
This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in patients with type 2 diabetes
This medicine helps improve blood glucose control when used alongside dietary and exercise therapies in patients with type 2 diabetes. Sitagliptin and metformin work together to effectively lower blood glucose levels, providing a positive impact on blood sugar management for patients. Therefore, this medicine is used to improve blood glucose control in type 2 diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medicine consists of sitagliptin and metformin, and is used for diabetes treatment. Firstly, serious allergic reactions may occur with this medicine, so if symptoms such as rash, hives, or swelling of the face or neck appear, discontinue use immediately and consult a doctor. Additionally, there is a risk of pancreatitis, so if abdominal pain, vomiting, or nausea occur after taking the medication, notify medical personnel immediately. Metformin contained in this medicine may cause a rare but fatal metabolic disorder called lactic acidosis, so if symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain occur, stop taking the medicine immediately and go to the hospital. Patients with impaired kidney function or specific health conditions such as dehydration, severe infections, or heart failure should not take this medicine, and it should be temporarily discontinued before and after tests involving iodine contrast agents. It is safest not to use this medicine in pregnant or breastfeeding women, or in children under 18 years of age. While taking this medicine, hypoglycemia may occur, so caution is needed during irregular meals or intense exercise, and special care is required when taking it alongside other hypoglycemic agents. Moreover, liver and kidney functions should be regularly tested to check for abnormalities, and monitoring through blood tests is advisable since vitamin B12 deficiency may occur. Excessive alcohol consumption can increase the risk of side effects from this medicine, so it should be avoided, and if surgery is scheduled, use should be discontinued 48 hours prior and restarted only after confirming normal kidney function post-surgery. Finally, there may be interactions when this medicine is taken with other medications, so it is essential to inform the doctor or pharmacist of any current medications.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly closed container to prevent air and moisture from entering, and it is recommended to be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medication's efficacy for a long time.
Pink oval film-coated tablets
Company packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.